novartis

Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment

Basel, January 9, 2026 – Novartis, a leading global innovative medicines company, today announced plans to build its fourth US…

7 hours ago

Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS

Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breakerScemblix…

2 months ago

PSMAddition data show Novartis Pluvicto delays progression to end-stage prostate cancer

Basel, October 19, 2025 – Novartis today presents new Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan) data from the Phase III PSMAddition…

3 months ago

Gateway to Growth: Innovation and Opportunity at the 8th CIIE

SHANGHAI, Aug. 29, 2025 /PRNewswire/ -- Amid a shifting global economy, the China International Import Expo (CIIE) continues to provide a…

4 months ago

ICPO Foundation co-founded the RLT Angels Association with the aim of growing access to Radiotheranostics to one million patients

Further founding members include the European Association of Nuclear Medicine (EANM), GE HealthCare, Novartis, and RayzeBio, a Bristol Myers Squibb…

7 months ago

NYSE Content Advisory: Pre-Market update + Wall Street reopens after Juneteenth

NEW YORK, June 20, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from…

7 months ago

Novartis Pluvicto demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer

Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant…

7 months ago